NCT07813572
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 2026 to Oct 20, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression-free survival (PFS)
Timeframe: up to 3 years
Overall survival (OS)
Timeframe: up to 5 years
Secondary (2)
PFS
Objective response rate (ORR)
Arms and interventions
ZG005+BevacizumabExperimental
ZG005 20 mg/kg administered intravenously every 3 weeks (Q3W) + Bevacizumab(Avastin) 15 mg/kg administered intravenously Q3W
Sintilimab Plus BevacizumabActive comparator
Sintilimab 200 mg administered intravenously Q3W + Bevacizumab (达攸同) 15 mg/kg administered intravenouslyQ3W
Drugs: ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab, Bevacizumab
Sites
1 site in 1 country
- Nanjing Tianyinshan HospitalNanjing, Jiangsu, China